Retrospective Analysis of Clinical Factors Associated with a Greater Benefit with Axitinib in Metastatic Renal Cancer. (Axilong study) [Análisis Retrospectivo De Factores Clínicos Asociados A Un Mayor Beneficio Con Axitinib En Cáncer Renal Metastásico. (Estudio Axilong)]
Phase of Trial: Phase IV
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms AXILONG
- Sponsors Pfizer
- 09 Oct 2018 Planned End Date changed from 30 Sep 2018 to 30 Jun 2019.
- 09 Oct 2018 Planned primary completion date changed from 30 Sep 2018 to 30 Jun 2019.
- 31 May 2018 New trial record